One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan
Podos S.D.a · Trachtman H.b · Appel G.B.c · Bomback A.S.c · Dixon B.P.d · Wetzels J.F.M.e · Cook H.T.f · Parikh S.V.g · Pickering M.C.f · Tumlin J.h · Langman C.B.i · Lightstone L.f · Sperati C.J.j · Daina E.k · Bouman K.P.l · Rice K.m · Thanassi J.A.a · Huang M.a · Nester C.n · Remuzzi G.k
doi : 10.1159/000527166
Vol. 53, No. 10, 2022
C3 glomerulopathy (C3G) is a rare, progressive kidney disease resulting from dysregulation of the alternative pathway (AP) of complement. Biomarkers at baseline were investigated in patients with C3G who participated in two phase 2 studies with the factor D (FD) inhibitor, danicopan.
Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies
Nester C.a · Appel G.B.b · Bomback A.S.b · Bouman K.P.c · Cook H.T.d · Daina E.e · Dixon B.P.f · Rice K.g · Najafian N.g · Hui J.g · Podos S.D.h · Langman C.B.i · Lightstone L.d · Parikh S.V.j · Pickering M.C.d · Sperati C.J.k · Trachtman H.l · Tumlin J.m · de Vries A.P.J.n · Wetzels J.F.M.o · Remuzzi G.e
doi : 10.1159/000527167
C3 glomerulopathy (C3G) is an ultrarare, chronic and progressive nephropathy mediated by dysregulation of the alternative pathway of complement (AP), with poor prognosis and limited treatment options.
Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials
Agarwal R.a · Anand S.b · Eckardt K.-U.c · Luo W.b · Parfrey P.S.d · Sarnak M.J.e · Solinsky C.M.b · Vargo D.L.b · Winkelmayer W.C.f · Chertow G.M.g
doi : 10.1159/000528443
Anemia frequently occurs in chronic kidney disease (CKD), is associated with poor quality of life and cardiovascular outcomes, and its treatment represents a considerable economic burden to the healthcare system.
Hemodialysis Effects on Autonomic Function: Results of Linear and Nonlinear Analysis of Heart Rate Variability at Rest and in Response to Physical and Mental Stress Tests
Faitatzidou D.a · Dipla K.b · Theodorakopoulou M.P.a · Koutlas A.b · Karagiannidis A.a · Alexandrou M.-E.a · Tsouchnikas I.a · Giamalis P.a · Dimitriadis C.a · Zafeiridis A.b · Papagianni A.a · Sarafidis P.a
doi : 10.1159/000528322
Cardiac arrhythmias are the most common cause of death in hemodialysis. Autonomic dysfunction plays a central role in this arrhythmogenic background. Previous studies on hemodialysis-related changes in heart rate variability (HRV) give contradictory results.
Factors Affecting the Decision to Initiate Dialysis: A National Survey of United States Nephrologists
Mathur V.S.a · Wesson D.E.b · Li E.c · Tangri N.d
doi : 10.1159/000528167
The percentage of patients initiating dialysis at an estimated glomerular filtration rate (eGFR) ≤9 mL/min/1.73 m2 decreased between 2000 and 2018 in the USA.
Cardiovascular Risk Prediction in Chronic Kidney Disease
Li X.a,b · Lindholm B.b
doi : 10.1159/000528560
As one of the main complications of chronic kidney disease (CKD), the incidence of cardiovascular disease (CVD) in CKD patients is high. CVD risk is markedly increased even at early stages of CKD, and CVD deaths account for half of all known causes of mortality in end-stage renal disease patients.
Metabolic Basis and Pathogenesis of Skeletal Muscle Dysfunction as Cause of Frailty in Chronic Kidney Disease
Wesson D.E.a · Mathur V.b · Tangri N.c
doi : 10.1159/000526679
Frailty is common in patients with chronic kidney disease (CKD), as is its physical component, phenotypic frailty, and each contributes to CKD-related disability and are associated with increased mortality.
Proteinuria and Risk for Heart Failure in 55,191 Patients Having History of Cancer
Suzuki Y.a,b · Kaneko H.a,c · Okada A.d · Fujiu K.a,c · Michihata N.e · Jo T.e · Takeda N.a · Morita H.a · Kamiya K.f · Matsunaga A.f · Ako J.g · Node K.h · Nangaku M.i · Yasunaga H.j · Komuro I.a
doi : 10.1159/000527703
We examined the association of proteinuria with the risk for heart failure (HF) and other cardiovascular disease (CVD) events in patients with prior history of breast, colorectal, or stomach cancer using a nationwide population-based database.
Clinical Effectiveness of Calcium Oxalate Stone Treatments
Gutbrod J. · Keys McKay C.C. · Coe L. · Bergsland K. · Coe F. · Worcester E. · Prochaska M.
doi : 10.1159/000527940
Lowering kidney stone risk and urine calcium oxalate supersaturation is a primary clinical focus for kidney stone prevention and can be achieved with multiple strategies. Common strategies include advice to increase fluid intake, restrict dietary sodium, or prescribing a thiazide-type diuretic.
